The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) delivered a series of unexpected decisions regarding childhood vaccinations, sparking debate and raising concerns among health experts. In a chaotic turn of events, the committee unexpectedly delayed a vote on proposed changes to the newborn hepatitis B vaccination schedule. The initial proposal suggested delaying the first dose until at least one month of age, a significant departure from the current practice of administering the vaccine at birth, a standard procedure since 1991. This established practice has been credited with dramatically reducing hepatitis B infections in infants, from an average of 18,000 cases annually to approximately 20 today. Hepatitis B infection in children often leads to chronic conditions, with potential long-term liver damage, increasing the risk of cirrhosis, liver cancer, and the need for transplants. The unexpected delay in voting on this crucial change left many questioning the committee's rationale.
Adding to the confusion, the ACIP reversed course on a previous vote concerning the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Following an initial vote to recommend against its use in young children, a subsequent vote on Friday reversed this decision, bringing the Vaccines for Children program in line with the current MMRV recommendations. This erratic voting process raised concerns about inconsistencies in the committee's decision-making processes and the potential for disparate impact on various socioeconomic groups.
Dr. Jason Goldman, president of the American College of Physicians and a non-voting ACIP liaison member, expressed considerable apprehension regarding the conflicting votes on the MMRV vaccine. He highlighted the potential for unequal access to healthcare based on socioeconomic factors, suggesting the lack of sufficient data to justify changes to established vaccination protocols. He implied that the reversal of the MMRV recommendation revealed an absence of supporting evidence to alter current practices and indicated no demonstrable harm from continuing with the existing vaccination schedules.
The ACIP's recommendations are not yet final. The Department of Health and Human Services (HHS) will thoroughly analyze the implications of these recommendations, particularly concerning insurance coverage, before the acting CDC director makes a final decision. This tumultuous series of events underscores the complexities and high stakes involved in shaping national vaccination policies, highlighting the ongoing need for transparent and well-supported decision-making processes.
---
Originally published at: https://edition.cnn.com/2025/09/19/health/cdc-acip-hepatitis-mmrv-covid-vaccine
